PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2016; 16: 369.
Published online 2016 June 21. doi:  10.1186/s12885-016-2403-1
PMCID: PMC4916533

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

Erratum

After publication of the original article [1], the authors noticed an error in the Acknowledgements section. The Acknowledgement contains missing information. The correct version of the Acknowledgements section is included below:

Acknowledgements

The research was funded in part by AstraZeneca and carried out at, and supported by, the National Institute for Health Research (NIHR UCLH Clinical Research Facility and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). Central coordination of the study was supported by Cancer Research UK (Grant reference C1813/A12155) and AstraZeneca. Conduct of the trial at hospital sites was supported through the National Institute of Health Research Clinical Research Network and AstraZeneca. We also acknowledge the support of the AMMF (www.ammf.org.uk/) and the IBTCC (International Biliary Tract Cancer Collaboration). JB is partly funded by the UCLH/UCL NIHR Biomedical Research Centre.

Footnotes

The online version of the original article can be found under doi:10.1186/s12885-016-2174-8.

References

1. Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16:153. doi: 10.1186/s12885-016-2174-8. [PMC free article] [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central